2010
DOI: 10.1002/cmdc.201000378
|View full text |Cite
|
Sign up to set email alerts
|

Integrated Synthetic, Pharmacological, and Computational Investigation of cis‐2‐(3,5‐Dichlorophenylcarbamoyl)cyclohexanecarboxylic Acid Enantiomers As Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 4

Abstract: 2-(3,5-Dichlorophenylcarbamoyl)cyclohexanecarboxylic acid (1) is a potent and selective positive allosteric modulator of metabotropic glutamate receptor subtype 4 (mGluR4). The activity of 1 was reported to reside in the cis diastereomer with equal potency between its enantiomeric forms (Niswender et al., Mol. Pharmacol. 2008, 74, 1345-1358). In the present study, the asymmetric synthesis of each of the cis enantiomers was performed, and their activities were compared with that of the racemic trans. In our ass… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
13
0

Year Published

2011
2011
2014
2014

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 10 publications
(14 citation statements)
references
References 39 publications
1
13
0
Order By: Relevance
“…However, this was later hypotheized to be due to an unusual racemization reaction, as resynthesis of the enantiomers by an independent group showed the activity to reside solely with one enantiomer ((1R, 2S)-15). 51 The SAR reported for this series was unremarkable, as little change was tolerated in various domains of the scaffold. 52 Interestingly, 15 has only partial agonist activity in the mGlu4 assay and does not compete with PHCCC binding.…”
Section: Mglu4 Ligandsmentioning
confidence: 86%
“…However, this was later hypotheized to be due to an unusual racemization reaction, as resynthesis of the enantiomers by an independent group showed the activity to reside solely with one enantiomer ((1R, 2S)-15). 51 The SAR reported for this series was unremarkable, as little change was tolerated in various domains of the scaffold. 52 Interestingly, 15 has only partial agonist activity in the mGlu4 assay and does not compete with PHCCC binding.…”
Section: Mglu4 Ligandsmentioning
confidence: 86%
“…However, the rich conformational flexibility of the cyclohexane ring and the VU0155041 enantiomer distinction at the receptor represent an attractive platform to study the structural and functional features of allosteric potentiation at the mGlu 4 receptor. In this context, the different activities between the cis-rac-2 (EC 50 : 2.8 mm) and trans-rac-3 (EC 50 : 22.0 mm) diastereomers, and the differential activity found for the enantiomers [13] of 2 (1R,2S)-2 (EC 50 : 0.8 mm) and (1S,2R)-2 (EC 50 > 100 mm) appear to define a very specific interaction of these ligands with the mGlu 4 receptor. The presence of 1,2-disubstitution in these compounds delineates different conformations which, in the case of the more stable chair conformers, can place the groups in either axial or equatorial arrangement.…”
Section: Introductionmentioning
confidence: 97%
“…nally reported, [10] the two VU0155041 enantiomers differed in pharmacological activity, with (1R,2S)-2 being more potent than (1S,2R)-2. [13] In addition, two conformations for each of the cis-VU0155041 and trans-VU0155040 diastereomers were characterized by high-level quantum mechanical (QM) calculations. The enantioselective nature of recognition of this family in the mGlu 4 receptor was consistently confirmed with the structurally related cis-1,2-cyclohexanediamides, [14] with the (1S,2R) Lu AF21934 enantiomer more active than the (1R,2S) Lu AF21935 enantiomer.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations